Showing posts with label fallopian tube. Show all posts
Showing posts with label fallopian tube. Show all posts

Friday, February 8, 2013

New surgery helps prevent ovarian cancer


New surgery helps prevent ovarian cancer


KGW Staff
Posted on February 7, 2013 at 3:59 PM

PORTLAND, Oregon -- Doctors at a Portland hospital have joined some others across the nation and Canada in following a new recommendation aimed at preventing one of the deadliest forms of cancer in women.
“This is something so simple that could save a lot of lives,” said Dr. Nathalie Johnson, the Medical Director of the Legacy Cancer Institute. Johnson is recommending women who have tubal ligations or hysterectomies have their fallopian tubes removed.
"It’s because researchers have found the tubes attract cancer cells which can eventually encase the ovary," she said. "You could actually find a normal ovary wrapped in cancer and realize the cancer was starting in the fallopian tube and not the ovary."
The recommendation is supported by research on thousands of women. Legacy researcher Dr. Ann Smith-Shedev has studied the connection for more than a decade.
“We think this could cut the most common type of ovarian cancer by up to 70 percent,” Shedev said.
The Legacy Cancer Institute is the first program in Oregon to make the recommendation that women consider the fallopian tube removal if they’re scheduling a tubal ligation or hysterectomy.
“We’d like to raise awareness and hopefully it can become the standard here in Oregon and across the country,” said Johnson.


** I had several massive experimental surgeries in the early 1970's for lymphedema at Good Samaritan Hospital, which is now Legacy. My questions are, "is this really the answer?  Have you also warned your patients about the possibility of leg or abdominal lymphedema from such a surgery?"  Your peers in the 1960's at the Oregon Health Sciences University wrote a very interesting article about abdominal/leg lymphedema from an abdominal surgery. Pat**

Friday, February 1, 2013

Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin.


Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin.


Jan 2013

Source

Women's College Research Institute, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.

Abstract


Differentiating ovarian tumors based on developmental pathway may further our understanding of the disease. Traditionally,ovarian cancers were thought to arise from the ovarian surface epithelium; however, recent evidence suggests some tumors originate in the fallopian tube. We classified cases in a population-based case-control study (NECC) and two cohort studies (NHS/NHSII) by tumor dominance, a proxy for tissue of origin. Dominant tumors (likely ovarian origin) are restricted to one ovary or are at least twice as large on one ovary compared to the other. Ovarian cancer risk factors were evaluated in relation to dominant and non-dominant tumors (likely tubal origin) using polytomous logistic regression (NECC) or competing risks Cox models (NHS/NHSII). Results were combined using random-effects meta-analyses. Among 1,771 invasive epithelialovarian cancer cases, we observed 1,089 tumors with a dominant mass and 682 with no dominant mass. Dominant tumors were more likely to be mucinous, endometrioid, or clear cell, whereas non-dominant tumors were more likely to be serous. Tubal ligation, two or more births, endometriosis, and age were more strongly associated with dominant (RRs = 0.60, 0.83, 1.58, 1.37, respectively) than non-dominant tumors (RRs = 1.03, 0.93, 0.84, 1.14 p-difference = 0.0001, 0.01, 0.0003, 0.01, respectively). These data suggest that risk factors for tumors putatively arising from ovarian versus fallopian tube sites may differ; in particular, reproductive factors may be more important for ovarian-derived tumors. As this is the first study to evaluate ovarian cancer risk factors by tumor dominance, these results need to be validated by other studies.


Wednesday, September 26, 2012

New insights into ovarian cancer pathology.


New insights into ovarian cancer pathology.


Sept 2012

Source

Department of Pathology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.

Abstract


Malignant epithelial tumors (carcinomas) are the most common ovarian cancers and also the most lethal gynecological malignancies. Based on histopathology and molecular genetic alterations, ovarian carcinomas are divided into five main types [high-grade serous (70%), endometrioid (10%), clear-cell (10%), mucinous (3%), and low-grade serous carcinomas (<5%)] that account for over 95% of cases. These types are essentially distinct diseases, as indicated by differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, and molecular events during oncogenesis, response to chemotherapy, and prognosis.
For a successful specific treatment, reproducible histopathological diagnosis of the tumor cell type is critical. The five tumor types are morphologically diverse and resemble carcinomas of the uterus. Actually, recent investigations have demonstrated that a substantial number of cancers, traditionally thought to be primary ovarian tumors (particularly serous, endometrioid, and clear-cell carcinomas), originate in the fallopian tube and the endometrium and involve the ovary secondarily. This presentation summarizes recent advances in the molecular pathology which have greatly improved our understanding of the biology of ovarian carcinoma and are also relevant to patient management.